araag2/HINT huggingface dataset:
Clinical trial NCT01842893 (phase 3, status: completed)
Conditions: breakthrough pain, cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fentanyl ethypharm
SMILES: CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          1. Written informed consent

          2. Malignant solid tumor or a hematological malignancy causing cancer-related pain

          3. Background opioid treatment at a stable dose for at least a week

          4. One to four episodes of breakthrough pain per day

        Main exclusion criteria:

          1. Hypersensitivity to fentanyl or to any of the excipients

          2. Intrathecal opioids

          3. Recent history of substance abuse

          4. Recent or planned therapy that would alter pain

          5. Moderate or severe hepatic or renal disease
Clinical trial NCT00317746 (phase 3, status: completed)
Conditions: depression, hiv infections, hepatitis c
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, Z21, B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: citalopram, placebos
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV+ adults with chronic HCV infection requiring therapy and with no contraindications
             to PEG-IFN/ribavirin will be enrolled.

        Exclusion Criteria:

          -  Subjects with prior suicide attempt, active depression, treatment with antidepressants
             within 6 months of study entry or with other psychiatric disorders will be excluded.
Clinical trial NCT01120600 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: odanacatib, placebo for odanacatib
SMILES: CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is a male between 40 and 95 years of age

          -  Has osteoporosis

          -  Has anatomy suitable for dual energy x-ray absorptiometry (DXA) scan of the lumbar
             spine and and hip

          -  Is ambulatory

        Exclusion Criteria:

          -  Is currently on oral bisphosphonates or other treatment for osteoporosis

          -  Had previous hip fragility fracture and is a candidate for standard of care therapy

          -  Has had a fragility fracture (vertebral or non-vertebral fractures indicating reduced
             bone strength) within 12 months

          -  Has had more then one previous vertebral fracture

          -  Has been diagnosed with metabolic bone disorder other than osteoporosis

          -  Is Vitamin D deficient

          -  Has a history of renal stones

          -  Has active parathyroid disease

          -  Has history of thyroid disease not well controlled by medication

          -  Is diagnosed with secondary osteoporosis

          -  Has a daily calcium intake of <1,200 mg and is unwilling to take study prescribed
             supplements or increase dietary intake, such that his daily calcium intake is at least
             1200 mg

          -  Has a history of malignancy ≤5 years prior to signing informed consent

          -  Has been diagnosed with hypogonadism due to causes that affect multiple organ and body
             systems
Clinical trial NCT00716859 (phase 3, status: completed)
Conditions: glaucoma
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: timolol, latanoprost
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female of 18 years of age or under

          -  Diagnosis of glaucoma

          -  IOP of 22 mmHg or above in at least 1 eye

        Exclusion Criteria:

          -  Require surgery for acute angle closure

          -  Have had prior cyclodestructive procedures

          -  Have a history of ocular trauma or surgery in either eye within 3 months of the
             baseline visit
Clinical trial NCT01395147 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: lu aa21004
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Has completed the double-blind treatment period of the preceding study (CCT-003)

          2. Signs and dates a written, informed consent form for this study, different from that
             for the preceding study (CCT-003).

          3. Has CGI-S score improved at least one point at completion of the 8-week double-blind
             treatment period compared to the Baseline Visit in the preceding study (CCT-003).

          4. In the opinion of the investigator, the subject appears to benefit from long-term
             treatment of Lu AA21004.

        Exclusion Criteria:

          1. Diagnosed with the following disorder or symptom in the preceding study (CCT-003):

               -  Any current psychiatric disorder other than MDD as defined in a Diagnostic and
                  Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR).

               -  Any substance-related disorder (except nicotine and caffeine-related disorders)
                  as defined in the DSM-IV-TR.

               -  Clinically significant neurological disorder (including epilepsy).

               -  Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple
                  sclerosis, Huntington's disease, etc.).

               -  Any DSM-IV-TR axis II disorder that might compromise this study.

          2. Is at significant risk of suicide, or had a score ≥5 on Item 10 (suicidal thoughts) of
             the MADRS or attempted suicides during the preceding study (CCT-003)
Clinical trial NCT01005901 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: glycopyrronium bromide, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        1. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic
        Obstructive Lung Disease (GOLD) Guidelines, 2008) and:

          -  Smoking history of at least 10 pack-years

          -  Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value

          -  Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

        Exclusion Criteria:

          1. Patients who have had a lower respiratory tract infection within 6 weeks prior to
             Visit 1

          2. Patients with concomitant pulmonary disease

          3. Patients with a history of asthma

          4. Any patient with lung cancer or a history of lung cancer

          5. Patients with a history of certain cardiovascular comorbid conditions

          6. Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          7. Patients in the active phase of a supervised pulmonary rehabilitation program

          8. Patients contraindicated for tiotropium or ipratropium treatment or who have shown an
             untoward reaction to inhaled anticholinergic agents Other protocol-defined
             inclusion/exclusion criteria may apply
Clinical trial NCT00136318 (phase 3, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: escitalopram, placebo, peginterferon alfa-2a, ribavirin
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis C infection defined as positive anti-HCV antibodies and serum
             HCV-RNA >1000 IU/ml, naive to antiviral treatment

          -  age >18 years

        Exclusion Criteria:

          -  Antidepressive treatment within the last 3 years

          -  Psychiatric diseases including major depressive disorders in past medical history

          -  Active substance abuse during the last 12 months

          -  Pregnancy, lactation, wish to become pregnant

          -  Hepatitis B (HBV)/HIV-coinfection

          -  Decompensated liver disease, hepatocellular carcinoma, history of bleeding esophageal
             varices

          -  Neutropenia (<1500/ul), thrombocytopenia (<70/nl), anemia (<12g/dl in females, <13g/dl
             in males)

          -  History of autoimmune disease

          -  History of organ transplantation, concomitant liver disease, severe cardiopulmonary
             disease, hemolytic anemia, malignant disease
Clinical trial NCT01172938 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: apremilast 20mg, apremilast 30mg, placebo + 20 mg apremilast, placebo + 30 mg apremilast
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged ≥ 18 years at time of consent.

          -  Have a diagnosis of Psoriatic Arthritis (PSA, by any criteria) of ≥ 6 months duration.

          -  Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at time of
             screening.

          -  Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)

          -  May not have axial involvement alone

          -  Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine

          -  Have ≥ 3 swollen AND ≥ 3 tender joints.

          -  Males & Females must use contraception

          -  Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose
             oral corticosteroids allowed.

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  History of allergy to any component of the investigational product.

          -  Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.

          -  Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF)
             blocker
Clinical trial NCT01389323 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, peg-interferon alfa-2a, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants chronically infected with Hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load of ≥10,000 IU/mL at screening

          -  No previous exposure to interferon formulation, ribavirin or HCV direct antiviral
             agent

          -  Self-described as Black-African American, Latino or White-Caucasian

          -  Results of a liver biopsy obtained ≤36 months prior to first treatment compensated
             cirrhotics with HCV liver biopsy from any time prior to first treatment.

        Compensated cirrhotics were capped at approximately 25%

        Exclusion Criteria:

          -  Evidence of decompensated liver disease

          -  Documented or suspected Hepatocellular carcinoma (HCC)

          -  Positive for Hepatitis B or HIV 1/HIV 2 antibody at screening
Clinical trial NCT00695396 (phase 3, status: terminated)
Conditions: myelodysplastic syndromes, anemia
ICD codes: D46.9, D46.C, D46.Z, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: placebo, epoetin alfa, placebo, epoetin alfa
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    the study was stopped due to low subject enrollment. no safety issue or other concern factored
    into this decision.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MDS according to protocol-specified criteria via bone marrow studies
             performed within 12 weeks before randomization

        Exclusion Criteria:

          -  No prior or concurrent treatment with epoetin alfa or any other approved or
             experimental erythropoietin stimulating agents (ESAs) within the previous 12 months
             before randomization

          -  No prior use of approved or experimental agents for the treatment of MDS or recent
             treatment with granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage
             colony stimulating factor (GM-CSF) for the treatment of neutropenia

          -  Patients must not have secondary MDS or anemia caused by factors other than MDS
             (including iron deficiency, vitamin B12 or folate deficiencies, hemolysis, chronic
             renal failure, or gastrointestinal bleeding)

          -  No history (within 12 months) of deep venous thrombosis

          -  or history (within 6 months) of stroke, acute coronary syndrome or other arterial
             thrombosis

          -  Not currently receiving therapeutic anticoagulants or have uncontrolled hypertension

          -  No uncontrolled disease or dysfunction deemed clinically significant by the
             Investigator not attributable to MDS
Clinical trial NCT00311896 (phase 3, status: terminated)
Conditions: cancer, thrombosis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: bemiparin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor stopped due to difficulties to recruit 402 patients required by protocol
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over 18 years old of either sex who have given their informed consent to
             participate in the study.

          -  Patients with a neoplastic process, with a CVC for the administration of anti-tumoral
             treatment or any other treatment related to the neoplastic process.

          -  Patients with a platelet count above 30,000/mm3.

          -  Patients with no hemorrhagic symptomatology at the time of their inclusion

        Exclusion Criteria:

          -  Patients with a history of clinically evident hemorrhagic episodes and/or with
             increased bleeding due to any other homeostatic alteration that contraindicates
             anticoagulant treatment and/or in the past two months have presented at least one of
             the following: active hemorrhaging or organic lesions susceptible to bleeding (e.g.
             active peptic ulcer, hemorrhagic cerebrovascular accident, aneurysms).

          -  Major surgery in the past two months.

          -  Known hypersensitivity to LMWH, heparin or substances of porcine origin.

          -  Patients with congenital or acquired bleeding diathesis.

          -  Damage to or surgical interventions of the central nervous system, eyes and ears
             within the past 6 months.

          -  Acute bacterial endocarditis or slow endocarditis.

          -  Patients with a history of heparin-associated thrombocytopenia.

          -  Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic
             insufficiency (with values of AST and/or ALT > 5 times the normal value established by
             the reference range of the local hospital laboratory).

          -  Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
             blood pressure over 120 mmHg).

          -  Patients with suspected inability/or inability to comply with treatment and/or
             complete the study.

          -  Patients who are participating in another clinical trial or have done so in the past
             30 days.

          -  Patients with a life expectancy less than 3 months.

          -  Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant
             during the study.

          -  Patients on treatment with anticoagulants or who have been on treatment during the
             week previous to insert the CVC (including prophylaxis with heparin for hepatic
             veno-occlusive disease).

          -  Patients diagnosed with acute leukemia or awaiting a transplant from hematopoietic
             progenitors during the 90 days of the study.
Clinical trial NCT00325637 (phase 3, status: completed)
Conditions: hypertension, stroke
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, G46.4, G46.3, Z82.3
Drugs: cilnidipine
SMILES: COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Ischemic stroke patients with hypertension

        Exclusion Criteria:

          -  Cardioembolic stroke patients

          -  Severe hypertensive patients

          -  Secondary hypertensive patients
Clinical trial NCT00093288 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: bupropion xl
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current
             episode for at least 8 weeks.

        Exclusion Criteria:

          -  Patient has current or past history of seizure disorder or brain injury.

          -  Patient has a diagnosis of anorexia or bulimia within the past 12 months.

          -  Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic
             disorder(s).

          -  Patient has had a myocardial infarction within 1 year or a history of uncontrolled
             hypertension or unstable heart disease with 6 months.
Clinical trial NCT00691262 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: tacrolimus ointment
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patient may be male or female of any ethnic group

          -  Patient is aged 2 years to 15 years (not having completed his/her 16th birthday) and
             suffers from moderate to severe atopic dermatitis (Rajka/Langeland score of at least
             4.5).

          -  Patient known to be responsive to topical steroids

          -  Patient's legal representative has given written informed consent. If the patient is
             capable of understanding the purposes and risks of the trial written informed consent
             has been obtained from the patient as well. Female patients of childbearing potential
             must agree to maintain adequate birth control practice during the trial period and
             during the first four weeks after the end of the study

          -  Patient meets the following wash-out criteria:

               -  Topical corticosteroids

               -  Systemic corticosteroids (for the treatment of AD only)

               -  Systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate)

               -  Other investigational drugs

               -  Light Treatments (UVA, UVB)

          -  Patient has not taken/patient and legal representative agree that the patient does not
             take for the complete study period any medication or therapy prohibited by the
             protocol

        Exclusion Criteria:

          -  Patient has a genetic epidermal barrier defect such as Netherton's syndrome or
             generalised erythroderma

          -  Patient is pregnant or breast-feeding

          -  Patient has a skin infection on the affected (and to be treated) area

          -  Patient has a known hypersensitivity to macrolides in general, to Tacrolimus or any
             excipient of the ointment

          -  Patient is simultaneously participating in any other drug trial or less than 28 days
             have passed between the end of the previous trial and this one

          -  Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or
             condition which, in the opinion of the investigator, may invalidate the communication
             with the investigator

          -  Patient is known to be HIV positive
Clinical trial NCT00328692 (phase 3, status: completed)
Conditions: heart failure, congestive
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: rolofylline, comparator: placebo (unspecified)
SMILES: CCCN1C2=C(NC(=N2)C23C[C@@H]4CC2C[C@H](C3)C4)C(=O)N(CCC)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. History of heart failure of at least 14 days duration for which diuretic therapy has
             been prescribed

          2. Hospitalized for acute heart failure syndrome requiring IV diuretic therapy.

          3. Impaired renal function

        Exclusion Criteria:

          1. Acute contrast induced nephropathy

          2. Ongoing or planned IV therapy for heart failure with positive inotropic agents,
             vasopressors, vasodilators, or mechanical support with the exception of IV nitrates

          3. BNP <500pg/mL or NT-pro-BNP <2000 pg/mL

          4. Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis

          5. Severe pulmonary disease

          6. Significant stenotic valvular disease

          7. Heart transplant recipient or admitted for cardiac transplantation

          8. Clinical evidence of acute coronary syndrome in the 2 weeks prior to screening

          9. Heart failure due to significant arrhythmias

         10. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive
             cardiomyopathy.

         11. Known hepatic impairment

         12. Non-cardiac pulmonary edema, including suspected sepsis

         13. Allergy to soybean oil or eggs

         14. History of seizure

         15. Stroke within 2 years

         16. History of or current brain tumor of any etiology

         17. Brain surgery within 2 years

         18. Encephalitis/meningitis within 2 years

         19. History of penetrating head trauma

         20. Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years

         21. History of, or at risk for, alcohol withdrawal seizures

         22. Advanced Alzheimer's disease

         23. Advanced multiple sclerosis

         24. Hgb <8 g/dL, Hct <25%, or the need for a blood transfusion

         25. Previous exposure to KW-3902